Mumbai, Dec. 23 -- Bioeq AG (Bioeq), a Swiss biopharmaceutical company, and Zydus Lifesciences(Zydus), an innovation-led life-sciences company with an international presence, today announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq's Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO(R), an interchangeable biosimilar of Lucentis(R) (Ranibizumab) for the U.S. market. The Biologics License Application (BLA) for NUFYMCO(R) has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025. This transaction marks an expansion of Zydus' U.S. biosimilar business, fol...